The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance

Tegally H, San JE, Cotten M, Tegomoh B, Mboowa G, Martin DP, Baxter C, Moir M, Lambisia A, Diallo A, Amoako DG, Diagne MM, Sisay A, Zekri A-RN, Barakat A, Gueye A-S, Sangare AK, Ouedraogo A-S, Sow A, Musa AO, ..., Huddleston J, ..., Bedford T, ..., Ramphal Y, Bediako Y, Naidoo Y, Butera Y, de Laurent ZR, Ouma AEO, von Gottberg A, Githinji G, Moeti M, Tomori O, Sabeti PC, Sall AA, Oyola SO, Tebeje YK, Tessema SK, de Oliveira T, Happi C, Lessells R, Nkengasong J, Wilkinson E (395 authors). 2022. Science 378: eabq5358.
PDF
tegally-sarscov2-in-africa.pdf
Supplement
tegally-sarscov2-in-africa-supp.pdf
DOI
10.1126/science.abq5358

Abstract

Investment in SARS-CoV-2 sequencing in Africa over the past year has led to a major increase in the number of sequences generated, now exceeding 100,000 genomes, used to track the pandemic on the continent. Our results show an increase in the number of African countries able to sequence domestically, and highlight that local sequencing enables faster turnaround time and more regular routine surveillance. Despite limitations of low testing proportions, findings from this genomic surveillance study underscore the heterogeneous nature of the pandemic and shed light on the distinct dispersal dynamics of Variants of Concern, particularly Alpha, Beta, Delta, and Omicron, on the continent. Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve, while the continent faces many emerging and re-emerging infectious disease threats. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century.